Memantine Vipharm

Memantine, the active ingredient in Memantine Vipharm, is a NMDA receptor antagonist presented as an oral tablet for systemic use. It is indicated for the symptomatic treatment of moderate to severe Alzheimer’s disease in adult patients, helping to improve cognition, function and behavior.

GNH USA supplies Memantine Vipharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Products are manufactured under EU GMP guidelines and undergo rigorous batch testing.

Memantine is indicated for the treatment of Alzheimer’s disease, a neurodegenerative disorder affecting cognition and function.

Alzheimer’s disease (cognitive symptoms): May help maintain or modestly improve memory and thinking abilities. Alzheimer’s disease (functional abilities): May support daily living activities and overall functional performance. Alzheimer’s disease (behavioral symptoms): May reduce agitation, aggression and other neuropsychiatric manifestations.

Common Side Effects: - Dizziness - Headache - Constipation - Confusion - Somnolence - Hypertension

Serious or Rare Side Effects: - Seizures - Cardiac arrhythmia - Severe allergic reactions (e.g., anaphylaxis, Stevens‑Johnson syndrome) - Hepatic dysfunction

Memantine should be used with caution in patients with the following considerations: - Renal impairment: assess renal function and adjust dose if necessary. - History of seizures: monitor closely for increased seizure activity. - Cardiovascular disease: observe blood pressure and heart rhythm. - Concomitant use of other NMDA antagonists: avoid additive neurotoxicity. - Psychiatric disorders: watch for worsening confusion or hallucinations. Store at ambient temperature: keep in the original container, protect from moisture and light.

Memantine may interact with several medicines; monitoring is advised.

Major Interactions (Avoid): - Amantadine: increased risk of neurotoxicity and seizures. - Ketamine: additive NMDA antagonism may exacerbate CNS effects. - Strong CYP3A4 inhibitors: may raise memantine plasma levels.

Moderate Interactions (Monitor Closely): - Anticholinesterase inhibitors (e.g., donepezil): may increase gastrointestinal side effects. - CNS depressants (e.g., benzodiazepines): may enhance sedation. - Antihypertensive agents: possible additive blood pressure lowering.